RB PHARMA AS
Operating
Investeringer i virksomheter og verdipapirer med relasjon til
utvikling av farmasøytiske produkter og tjenester.
Investeringer i aktiviteter relatert til farmasøytisk virksomhet,
farmasøytiske oppfinnelser eller relaterte områder.
Organization
- Chairman of the board
- PR
- Years since formation
- 6 years
- since Jul 16, 2019
- Type
- Limited company
- VAT registered
- No
- Number of employees
- 0
Ownership
- Number of shares and share classes
- 1,000
- 1 share class
- Total number of shareholders
- 1
- company
- Belongs to group of
Financials
- Annual total result 2024
- -4,635
- NOK
- Total equity 2024
- 151,258
- NOK
Last update: Sep 9, 2025
Management
Board
| Name | Role | Shares |
|---|---|---|
PR | Chairman | 25 % indirectly |
| Deputy Chair | - |
Top 10 individual shareholders
| Name | Role | Shares |
|---|---|---|
PR | Chairman | 25 % indirectly |
CP | - | 25 % indirectly |
JÅ | - | 25 % indirectly |
Last update: Apr 13, 2023
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| Ordinary shares | 1,000 | 100 % |
Shares owned by the RB PHARMA AS
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| Ordinary shares | 7,000 | 0.07 % |
Last update: Jun 2, 2025
Group structure
- Total operating income 2024: NOK 0Operating profit 2024: NOK -57,692Employees: 0
Financials
in NOK
Summary
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total operating income | 0 | 0 | 0 | 0 |
Annual Total Result | -4,635 | -4,485 | -1,342 | -1,138 |
Total assets | 401,158 | 405,792 | 411,620 | 411,627 |
Total liabilities | 249,900 | 249,900 | 251,242 | 249,900 |
Total equity | 151,258 | 155,892 | 160,378 | 161,726 |
P&L
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total operating income | 0 | 0 | 0 | 0 |
Total operating costs | 4,635 | 4,485 | 1,342 | 0 |
Operating result | -4,635 | -4,485 | -1,342 | 0 |
Financial income/costs | 0 | 0 | 0 | -1,138 |
Profit before tax | -4,635 | -4,485 | -1,342 | -1,138 |
Total tax & extraordinary income/cost | 0 | 0 | 0 | 0 |
Annual Total Result | -4,635 | -4,485 | -1,342 | -1,138 |
Balance overview
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total fixed assets | 245,000 | 245,000 | 245,000 | 0 |
Total current assets | 156,158 | 160,792 | 166,620 | 411,627 |
Total assets | 401,158 | 405,792 | 411,620 | 411,627 |
Short term debt | 4,900 | 4,900 | 6,242 | 0 |
Long term debt | 245,000 | 245,000 | 245,000 | 249,900 |
Total liabilities | 249,900 | 249,900 | 251,242 | 249,900 |
Contributed capital | 162,858 | 162,858 | 162,858 | 162,864 |
Retained earnings | -11,600 | -6,966 | -2,480 | -1,138 |
Total equity | 151,258 | 155,892 | 160,378 | 161,726 |
Total equity and liabilities | 401,158 | 405,792 | 411,620 | 411,626 |
Classification
21st company classification
BETA
Scaleup
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises